Share on StockTwits

Geron (NASDAQ:GERN) posted its quarterly earnings results on Monday. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06), Stock Ratings News reports.

Geron (NASDAQ:GERN) traded up 3.67% during mid-day trading on Monday, hitting $2.54. The stock had a trading volume of 2,167,873 shares. Geron has a 1-year low of $1.3138 and a 1-year high of $7.3629. The stock’s 50-day moving average is $2.6 and its 200-day moving average is $2.81. The company’s market cap is $398.6 million.

On the ratings front, analysts at MLV & Co
upgraded shares of Geron from a “hold” rating to a “buy” rating in a research note on Thursday, June 12th. They now have a $4.25 price target on the stock, up previously from $2.00. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Geron presently has a consensus rating of “Hold” and an average target price of $4.25.

Geron Corporation (NASDAQ:GERN) is a clinical-stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.